CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Senexin C
CAS :<p>Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.</p>Formule :C28H27N5ODegré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :449.55Bisindolylmaleimide X hydrochloride
CAS :<p>Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).</p>Formule :C26H25ClN4O2Degré de pureté :99.23%Couleur et forme :SolidMasse moléculaire :460.96Cdc7-IN-7
CAS :<p>Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.</p>Formule :C21H22N4O5Degré de pureté :98.78%Couleur et forme :SolidMasse moléculaire :410.42CDK9-IN-23
CAS :<p>CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].</p>Formule :C22H25ClN4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :428.91Senexin A hydrochloride
CAS :<p>Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].</p>Formule :C17H15ClN4Couleur et forme :SolidMasse moléculaire :310.78CDK9-IN-19
CAS :<p>CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.</p>Formule :C26H22F2N4O5Couleur et forme :SolidMasse moléculaire :508.47Riviciclib
CAS :<p>Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.</p>Formule :C21H20ClNO5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.84ML 315 hydrochloride
CAS :<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Formule :C18H14Cl3N3O2Couleur et forme :SolidMasse moléculaire :410.682(S)-Cdc7-IN-18
CAS :<p>'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'</p>Formule :C19H21N5OSCouleur et forme :SolidMasse moléculaire :367.47CDK7-IN-25
CAS :<p>CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].</p>Formule :C33H32N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :560.65Inixaciclib
CAS :<p>Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.</p>Formule :C26H30F2N6OCouleur et forme :SolidMasse moléculaire :480.55SZ-015268
CAS :<p>SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.</p>Formule :C25H38N8O3Couleur et forme :SolidMasse moléculaire :498.62CDK4/6-IN-15
CAS :<p>CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.</p>Formule :C21H27FN8SCouleur et forme :SolidMasse moléculaire :442.56CDK4/6-IN-17
CAS :<p>CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.</p>Formule :C27H28F4N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :540.56Cdc7-IN-12
CAS :<p>Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).</p>Formule :C16H14N2O2SCouleur et forme :SolidMasse moléculaire :298.36Xylocydine
CAS :<p>Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.</p>Formule :C12H14BrN5O5Couleur et forme :SolidMasse moléculaire :388.17CF53
CAS :<p>CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.</p>Formule :C24H25N7O2Degré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :443.5Cdk1/2 Inhibitor III
CAS :<p>Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.</p>Formule :C15H13F2N7O2S2Degré de pureté :99.07%Couleur et forme :SolidMasse moléculaire :425.44(R)-Simurosertib
CAS :<p>(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.</p>Formule :C17H19N5OSDegré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :341.43XY028-140
CAS :<p>XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.</p>Formule :C39H40N10O7Degré de pureté :98.59%Couleur et forme :SolidMasse moléculaire :760.8Debio-0123
CAS :<p>Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.</p>Formule :C26H28Cl2N6ODegré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :511.45AZD4573
CAS :<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Formule :C22H28ClN5O2Degré de pureté :99% - 99.51%Couleur et forme :SolidMasse moléculaire :429.94PPA-037
CAS :<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Formule :C25H27N7Couleur et forme :SolidMasse moléculaire :425.53CDK1-IN-7
CAS :<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Formule :C23H19ClN4O3Couleur et forme :SolidMasse moléculaire :434.88YL-1-9
CAS :<p>YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].</p>Formule :C22H23F3N2O3Couleur et forme :SolidMasse moléculaire :420.425CDK9 autophagic degrader 1
CAS :<p>CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.</p>Formule :C34H39N7O4S2Couleur et forme :SolidMasse moléculaire :673.848CDK9-IN-11
CAS :<p>CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].</p>Formule :C20H25N3O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :371.43RGB-286638
CAS :<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Formule :C29H37Cl2N7O4Couleur et forme :SolidMasse moléculaire :618.55Cimpuciclib tosylate
CAS :<p>Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.</p>Formule :C37H43FN8O4SCouleur et forme :SolidMasse moléculaire :714.85CDK2/4-IN-2
CAS :<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Formule :C18H20F3N7O3S2Couleur et forme :SolidMasse moléculaire :503.52CDK2 degrader 4
CAS :<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Formule :C23H26ClN3O5Couleur et forme :SolidMasse moléculaire :459.923CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Couleur et forme :SolidPROTAC CDK12/13 Degrader-1
<p>PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.</p>Couleur et forme :SolidCDK7-IN-33
CAS :<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Formule :C29H36N6O4SCouleur et forme :SolidMasse moléculaire :564.699CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Formule :C20H18N4O4Couleur et forme :SolidMasse moléculaire :378.38LZ9
CAS :<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Formule :C17H11F3N4O2Couleur et forme :SolidMasse moléculaire :360.29CDK1-IN-3
<p>CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.</p>Formule :C28H25ClF3N5O2Couleur et forme :SolidMasse moléculaire :555.98Haspin-IN-2
CAS :<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Formule :C12H8N4O3Couleur et forme :SolidMasse moléculaire :256.22CDK4-IN-1
CAS :<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Formule :C22H29ClN8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :440.97Cdc7-IN-10
CAS :<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Formule :C20H22F2N4O2SCouleur et forme :SolidMasse moléculaire :420.48DDO-6079
CAS :<p>DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.</p>Formule :C18H13ClN2O3Couleur et forme :SolidMasse moléculaire :340.76CDK7-IN-18
CAS :<p>CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.</p>Formule :C22H24F3N7OSCouleur et forme :SolidMasse moléculaire :491.53CLK1/2-IN-1
CAS :<p>CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.</p>Formule :C21H20F3N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :443.42TMX-3013
CAS :<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Formule :C17H14BrFN6O3SCouleur et forme :SolidMasse moléculaire :481.3CDK2-IN-8
<p>CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.</p>Formule :C22H25N5O3Couleur et forme :SolidMasse moléculaire :407.47CDK2-IN-31
CAS :<p>CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.</p>Formule :C37H52N6O5Couleur et forme :SolidMasse moléculaire :660.85CDK12/13 ligand 1
CAS :<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Formule :C26H26BrN5OCouleur et forme :SolidMasse moléculaire :504.42CDK1-IN-5
<p>CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.</p>Formule :C27H26ClN5OSCouleur et forme :SolidMasse moléculaire :504.05CDK5-IN-2
CAS :<p>CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).</p>Formule :C29H28FN5OCouleur et forme :SolidMasse moléculaire :481.56CDK8-IN-14
CAS :<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Formule :C18H13N3O2Couleur et forme :SolidMasse moléculaire :303.31GSK3-IN-10
CAS :<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Formule :C17H18F2N4O3Couleur et forme :SolidMasse moléculaire :364.347DB18
CAS :<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Formule :C24H18ClN7O3Couleur et forme :SolidMasse moléculaire :487.9(R)-Atuveciclib
CAS :<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Formule :C18H18FN5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :387.43CDK2-IN-18
CAS :<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Formule :C21H23N7O2SCouleur et forme :SolidMasse moléculaire :437.52CDK2 degrader 6
CAS :<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Formule :C23H22F5N5O3Couleur et forme :SolidMasse moléculaire :511.44INX-315
CAS :<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Formule :C19H21N7O3SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :427.48CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Formule :C27H35N5O2Couleur et forme :SolidMasse moléculaire :461.6CDK8-IN-11 hydrochloride
<p>CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.</p>Formule :C19H16ClF3N4O2Couleur et forme :SolidMasse moléculaire :424.8CDK9-IN-38
CAS :<p>CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.</p>Formule :C22H23N5O3SCouleur et forme :SolidMasse moléculaire :437.515CDK4/6-IN-13
CAS :<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Formule :C25H29N7OCouleur et forme :SolidMasse moléculaire :443.54CLK1/4-IN-1
<p>CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.</p>Formule :C18H14ClNO4SCouleur et forme :SolidMasse moléculaire :375.83Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Formule :C22H15ClFNOCouleur et forme :SolidMasse moléculaire :363.81CDK4/6-IN-24
CAS :<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Formule :C32H41N7O3Couleur et forme :SolidMasse moléculaire :571.713Zeltociclib
CAS :<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Formule :C18H20F3N4O2PCouleur et forme :SolidMasse moléculaire :412.346Cdc7-IN-18
CAS :<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Formule :C19H21N5OSCouleur et forme :SolidMasse moléculaire :367.47Cdc7-IN-11
CAS :<p>Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.</p>Formule :C20H22F2N4O2SCouleur et forme :SolidMasse moléculaire :420.48CDK2-IN-40
CAS :<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Formule :C16H21N7O2Couleur et forme :SolidMasse moléculaire :343.384CDK2-IN-30
CAS :<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Formule :C18H25N7O3SCouleur et forme :SolidMasse moléculaire :419.50CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Formule :C21H22N4OCouleur et forme :SolidMasse moléculaire :346.43CDDD11-8
CAS :<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Formule :C24H26N6Couleur et forme :SolidMasse moléculaire :398.50CDK2-IN-39
CAS :<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Formule :C14H15N3O4SCouleur et forme :SolidMasse moléculaire :321.352CDK4/9-IN-1
CAS :<p>CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.</p>Formule :C22H34N6O2Couleur et forme :SolidMasse moléculaire :414.544P162-0948
CAS :<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Formule :C20H15FN4O2Couleur et forme :SolidMasse moléculaire :362.357DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Formule :C18H26N4O3SCouleur et forme :SoildMasse moléculaire :378.49CTX-712
CAS :<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Formule :C19H17FN8O2Couleur et forme :SolidMasse moléculaire :408.39CDK7/12-IN-1
CAS :<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Formule :C25H34N8OCouleur et forme :SolidMasse moléculaire :462.59Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Formule :C12H8N4O2SCouleur et forme :SolidMasse moléculaire :272.28CDK7-IN-17
CAS :<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Formule :C24H26F3N6OPCouleur et forme :SolidMasse moléculaire :502.47CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Formule :C26H24ClN5SCouleur et forme :SolidMasse moléculaire :474.02PKMYT1-IN-7
CAS :<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Formule :C17H18FN5O3Couleur et forme :SolidMasse moléculaire :359.355CDK7-IN-31
CAS :<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Formule :C27H32F5N6O2PCouleur et forme :SolidMasse moléculaire :598.55Protein kinase inhibitor 11
CAS :<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463Cdc7-IN-8
CAS :<p>Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)</p>Formule :C19H21N5O2Couleur et forme :SolidMasse moléculaire :351.40CDK6-IN-1
CAS :<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Formule :C30H23N5Couleur et forme :SolidMasse moléculaire :453.54Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Formule :C22H15ClFNOCouleur et forme :SolidMasse moléculaire :363.81Protein Kinase Inhibitor 12
CAS :<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Formule :C14H14N4OSDegré de pureté :98.06%Couleur et forme :SolidMasse moléculaire :286.35YKL-1-116
CAS :<p>YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.</p>Formule :C34H38N8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :606.72CDK9/PARP-IN-1
CAS :<p>CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.</p>Formule :C38H34F2N8O3Couleur et forme :SolidMasse moléculaire :688.725Protein kinase inhibitor 13
CAS :<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458Cdc7-IN-19
CAS :<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Formule :C19H21N5O2Couleur et forme :SolidMasse moléculaire :351.40CDK8-IN-5
CAS :<p>CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.</p>Formule :C26H22N2O4Couleur et forme :SolidMasse moléculaire :426.46CDK4/6-IN-3
CAS :<p>CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.</p>Formule :C25H31FN8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.57SGC-CLK-1
CAS :<p>SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.</p>Formule :C19H15F3N6O2Couleur et forme :SolidMasse moléculaire :416.36p38α inhibitor 9
CAS :<p>p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.</p>Formule :C27H24FN3O3Couleur et forme :SolidMasse moléculaire :457.496GFB-12811
CAS :<p>GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.</p>Formule :C22H23F4N5ODegré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :449.44LY3143921 hydrate
CAS :<p>LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].</p>Formule :C16H14FN5O2Degré de pureté :98.43%Couleur et forme :SolidMasse moléculaire :327.31Tanuxiciclib
CAS :<p>Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.</p>Formule :C15H13FN6OCouleur et forme :SolidMasse moléculaire :312.308GSK-3/CDK5/CDK2-IN-1
CAS :<p>GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].</p>Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.433Tibremciclib
CAS :<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Formule :C28H32F2N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :518.6YK-2168
CAS :<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Formule :C16H18ClN5Couleur et forme :SolidMasse moléculaire :315.80
